InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025
InMode Ltd. (Nasdaq: INMD) reported Q2 2026 GAAP revenues of $95.6M, unchanged vs Q2 2025. Consumables and service rose 13% to $22.3M. GAAP net income was $17.1M ($0.29/diluted share). Cash and equivalents plus marketable securities totaled $501.1M at June 30, 2026. FY2026 outlook: revenues $365M-$375M and non-GAAP EPS $1.29-$1.34.
How this was made
The 30-second read
Why it matters
Traders can update models using the disclosed Q2 revenue and profitability metrics and re-anchor expectations to the FY 2026 revenue and non-GAAP EPS ranges. The explicit margin decline drivers (COGS, mix, sales team restructuring, higher marketing and G&A) frame what to watch in subsequent quarters.
Market read
A full earnings and guidance package with specific FY ranges and a completed buyback is likely to drive positioning around revenue stability versus margin compression.
What to watch
The company also completed a sizable share repurchase and appointed new CFO and board chair, which can affect investor perception of capital allocation and governance even if operating margins fell.
Background
InMode issued its Q2 2026 earnings release with quarterly results, margin commentary, capital position, share repurchase completion, executive appointments, and full-year 2026 guidance.
Ticker impact
InMode reported Q2 2026 GAAP revenues of $95.6M and guided FY 2026 revenues to $365M-$375M, plus non-GAAP EPS of $1.29-$1.34.
Likely near-term volatility driven by margin compression versus the stability in revenue, with direction depending on how investors weigh the FY non-GAAP EPS range.
The release discloses both quarterly datapoints (gross and operating margin down vs prior year) and a full-year outlook with specific revenue and non-GAAP EPS ranges, which are the primary decision inputs for traders.
Market effects
Signals ongoing cost pressure and mix effects in medical device equipment and consumables models, which can influence read-across for similar medtech names.
Notes Asia revenue at a quarterly record, suggesting regional demand strength that may affect regional medtech sentiment.
Israel conflict risk is mentioned as not materially affecting operations, which may be monitored by global investors for any future disruption.
Counterpoint
Revenue stability plus a defined FY non-GAAP EPS range could be interpreted as resilience, offsetting the margin compression narrative.
Key entities
- companyInMode Ltd.
Nasdaq-listed medical technology company reporting Q2 2026 results and providing FY 2026 guidance.
- executiveMoshe (Moshik) Itzkovich
Appointed Chief Financial Officer effective May 19, 2026, and quoted on revenue stability and expected stabilization through year-end.
- executiveDr. Shlomo Nass
Appointed Chairman of the Board effective May 19, 2026.
